RVMD250117P38000
- 0.00
- 0.000.00%
Revolution Medicines Newsroom
Barclays Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $72
Barclays Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $72
Barclays Reaffirms Their Buy Rating on Revolution Medicines (RVMD)
BofA Securities Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $80
Analysts' Top Healthcare Picks: Envista Holdings (NVST), Revolution Medicines (RVMD)
Revolution Medicines Is Maintained at Buy by UBS
Revolution Medicines Price Target Raised to $71.00/Share From $65.00 by UBS
Revolution Medicines Analyst Ratings
UBS Initiates Revolution Medicines(RVMD.US) With Buy Rating, Announces Target Price $71
Jefferies Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $86
Needham Maintains Revolution Medicines(RVMD.US) With Buy Rating, Cuts Target Price to $62
Wedbush Maintains Revolution Medicines(RVMD.US) With Buy Rating, Cuts Target Price to $67
Revolution Medicines Is Maintained at Outperform by Wedbush
Revolution Medicines Price Target Cut to $62.00/Share From $68.00 by Needham
Revolution Medicines Is Maintained at Buy by Needham
Revolution Medicines Analyst Ratings
H.C. Wainwright Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $72
HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $72
BofA Securities Maintains Revolution Medicines(RVMD.US) With Buy Rating, Announces Target Price $80
Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $87